GMP (Good Manufacturing Practice) Explained

“Good manufacturing process” is a common search variant of Good Manufacturing Practice (GMP) — the correct, internationally recognized name for the regulatory quality-assurance framework that governs how drugs, biologics, active pharmaceutical ingredients (APIs), and medical devices are produced. GMP is not a single rule but a family of related regulations — enforced by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), among others — that require consistent, documented, quality-controlled manufacturing processes. (Even the WHO’s own public guidance page uses the plural “manufacturing processes” phrasing informally, so the search variant isn’t surprising — the technical term is still “practice.”)

For most CASRAI readers, GMP is not the day-to-day concern it is for a commercial pharmaceutical manufacturer. But it becomes directly relevant to a research institution the moment a discovery moves from the lab bench toward a clinical trial, a licensing deal, or an Investigational New Drug (IND) application — which is exactly the translational point where research administrators, tech transfer offices, and clinical trial operations staff need to understand what GMP requires and when it applies.

What GMP Actually Regulates

GMP governs the production side of the product lifecycle: facilities, equipment, personnel qualification, raw-material sourcing, process validation, batch documentation, deviation handling, and final-product release testing. It exists to ensure a manufactured product is what its labeling says it is, is free of contamination or mix-ups, and is reproducible from batch to batch. The FDA’s summary is direct: GMP regulations “have the force of law” and require manufacturers, processors, and packagers of drugs, medical devices, and other regulated products to take proactive steps to ensure safety, purity, and effectiveness.

GMP is distinct from — but closely related to — the two other regulatory frameworks a research institution is more likely to already know:

Good Laboratory Practice (GLP) — 21 CFR Part 58 in the U.S. — governs the conduct of nonclinical (preclinical) laboratory studies submitted to support an FDA research or marketing application: controlled protocols, calibrated equipment, and a dedicated quality assurance unit, so regulators can trust the safety data.
Good Clinical Practice (GCP) — internationally harmonized as ICH E6 — governs the conduct of the clinical trial itself: participant protection, informed consent, data integrity, and investigator responsibilities. CASRAI’s ICH GCP dictionary entry covers this in detail.

Read together, GLP, GMP, and GCP form the three regulatory pillars a translational research program moves through in order: GLP validates the preclinical safety data, GMP ensures the investigational product itself is manufactured to a controlled standard, and GCP governs how that product is then tested in human participants. A research administrator supporting an investigator-initiated trial needs at least a working knowledge of all three, because a gap in any one of them can stall an IND submission or an FDA inspection finding.

The Regulatory Framework Behind GMP

There is no single global “GMP law” — instead, a set of harmonized but jurisdiction-specific regulations apply depending on the product type and the market:

U.S. drug cGMP — 21 CFR Parts 210 and 211. These regulations (the FDA also calls them “current GMP,” or cGMP, to signal that the required systems and technology must keep improving) cover facilities, personnel, equipment, production and process controls, packaging, labeling, and record-keeping for finished drug products.
U.S. device quality regulation — 21 CFR Part 820. As of February 2, 2026, the FDA’s device manufacturing regulation transitioned from the older Quality System Regulation (QSR) to the new Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference — harmonizing U.S. device manufacturing requirements with the international standard already used by most other regulators.
Active pharmaceutical ingredients — ICH Q7. The International Council for Harmonisation’s Q7 guideline sets GMP expectations specifically for API manufacturing (starting materials, intermediates, and bulk synthesis) and is the basis for Part II of the EU’s GMP framework.
European Union — EudraLex Volume 4. The EU’s “Rules Governing Medicinal Products” set out GMP for finished products (Part I) and APIs (Part II, based on ICH Q7).
World Health Organization — WHO GMP. Published through WHO’s Technical Report Series (with annexes covering sterile products, biologicals, and other categories), WHO GMP guidance is widely used as a baseline standard in jurisdictions without their own comprehensive GMP regulation, and is referenced in WHO prequalification programs.

A research institution manufacturing or sourcing an investigational product for a U.S. trial is generally working against 21 CFR 210/211 (or ICH Q7 if the material is an API); a device-focused program is working against the new QMSR; a multinational or EU-facing program needs to track EudraLex Volume 4 as well.

Why GMP Matters for Academic Research Institutions

GMP is not automatically triggered by every research lab that handles a chemical or biological compound. The FDA applies a phase-appropriate approach: under 21 CFR 210.2(c), most Phase 1 investigational drugs are exempt from the full scope of Part 211, reflecting the FDA’s 2008 guidance on cGMP for Phase 1 investigational drugs — a risk-based framework scaled to the small batch sizes and limited scope of early-phase work. That exemption ends once a drug moves into Phase 2 or Phase 3, or if it has already been used in a later-phase study or lawfully marketed — at that point, full Part 211 compliance applies.

This phase-based structure is exactly why GMP becomes a live compliance question for investigator-initiated IND holders and academic medical centers, not just commercial sponsors:

Investigator-initiated INDs. A faculty investigator who holds their own IND for a Phase 1 study is themselves the “sponsor” under FDA regulations and is responsible for ensuring the investigational product is manufactured under appropriate phase-appropriate GMP controls — the same accountability a commercial sponsor would carry, just executed by an academic research team.
Institutional GMP manufacturing facilities. A growing number of academic medical centers and universities operate their own current-GMP (cGMP) facilities — most visibly for cell and gene therapy products — specifically to support IND-enabling manufacturing for investigator-initiated and early-phase trials, rather than outsourcing entirely to contract manufacturers.
Federal translational-development support. NIH’s National Center for Advancing Translational Sciences (NCATS) runs the Bridging Interventional Development Gaps (BrIDGs) program, which provides academic investigators with no-cost access to IND-enabling development services — including GMP synthesis and formulation work — specifically to help move promising discoveries toward an IND filing. This is a concrete example of a federal program built around the exact translational gap where GMP compliance becomes a research administrator’s problem, not just a manufacturer’s.

GMP and Technology Transfer

GMP compliance is also a recurring checkpoint in university technology transfer and licensing. Research-grade material produced in an academic lab is almost never GMP-grade — different documentation, different facility controls, different validation burden. When a university licenses an early-stage therapeutic, biologic, or device to an industry partner (or spins the technology out into a startup), scaling the manufacturing process up to GMP standards is typically an explicit technology-readiness milestone in the license agreement or sponsored-research/collaboration agreement, and due diligence on the manufacturing pathway (can this be produced at GMP scale, at what cost, by whom) is a standard part of evaluating whether a discovery is licensable in the first place. Institutions that can demonstrate an existing GMP-compliant (or GMP-track) manufacturing pathway — whether in-house or through a contract manufacturing organization — are typically in a stronger negotiating position than those offering research-grade material alone.

Core GMP Compliance Obligations

Across the different jurisdiction-specific regulations above, GMP systems share a common structural core:

A documented quality management system — written standard operating procedures (SOPs) covering every step of production, not informal lab practice.
Facility and equipment qualification — validated, calibrated, and appropriately controlled (e.g., cleanroom classifications for sterile or cell-therapy manufacturing).
Personnel training and qualification — documented, role-specific, and repeated, not a one-time onboarding step.
Batch production and control records — a complete, contemporaneous, auditable record for every batch produced, including raw-material traceability.
Deviation and corrective/preventive action (CAPA) management — any departure from an approved procedure must be documented, investigated, and resolved before the affected material is released.
Change control and process validation — process changes are formally evaluated and revalidated, not made informally once a facility is operating.

These are the same categories an FDA GMP inspection (or an EMA/MHRA equivalent) will assess directly — which is why an institution planning to manufacture at GMP scale, even for a single investigator-initiated trial, should budget for the quality-system infrastructure well before the first batch is produced, not after.

Frequently Asked Questions

Is “good manufacturing process” the same thing as GMP?

Yes, in practical search terms — “good manufacturing process” and “good manufacturing practices” both refer to the same regulatory concept, Good Manufacturing Practice (GMP). The correct technical term used in the regulations themselves is “practice,” not “process,” but the phrasing varies in everyday use, including on some official sources.

Does GMP apply to a standard academic research lab?

Not to routine discovery-stage or basic-science research. GMP applies once material is being manufactured for use in humans (or for a marketing application) — most commonly when a lab or institutional facility is producing an investigational drug, biologic, or device component intended for an IND-supported clinical trial. Phase 1 investigational drugs carry a partial exemption from full drug GMP under 21 CFR 210.2(c), but that exemption narrows sharply once a product advances to Phase 2 or 3.

What’s the difference between GMP, GCP, and GLP?

GLP (21 CFR Part 58) governs how preclinical/nonclinical safety studies are conducted; GMP governs how the investigational product is manufactured; GCP (ICH E6) governs how the clinical trial itself is conducted with human participants. A single translational program typically has to satisfy all three at different stages.

What happens if an investigational product isn’t manufactured under appropriate GMP?

An FDA IND application can be placed on clinical hold, or an existing trial can be halted, if the agency determines the investigational product wasn’t manufactured, tested, or controlled under adequate GMP standards for its trial phase — a real risk for programs that treat manufacturing quality as an afterthought until an inspection or IND review surfaces it.

Is cGMP different from GMP?

No — “cGMP” (current Good Manufacturing Practice) and “GMP” are, in the FDA’s own usage, interchangeable in almost all contexts. The “current” simply signals that manufacturers are expected to use up-to-date systems and technology, not that cGMP is a separate, stricter standard.

Related CASRAI Resources

ICH GCP (Good Clinical Practice) — the clinical-trial-conduct counterpart to GMP
Clinical Trial Registration and Reporting Compliance
Federal Grant Compliance Checklist
Research Integrity & Compliance — cluster hub